




BioCAID is revolutionizing how artificial intelligence and machine learning are harnessed to build a new generation of “Assistive” knowledge services expanding user awareness and comprehension across silos of information and expertise within NIH MEDLINE and other libraries for the Biomedical, Life Science, Healthcare and related sciences.

BioCAID stands for Biomedical Conceptualization for Automated Intelligent Discovery


BIOCAID MISSION STATEMENT





**BioCAID Integrated Medline
Discovery Integration (IMDI)**

An intelligent query/discovery platform featuring Assistive AI for visual navigation and integration of publication libraries combined with advanced literature discovery and hypotheses validation algorithms for exploring conceptual Deep Learning and Semantics with Decision Support to enhance innovation discovery.

Our Mission Is To

- 

Find answers to complex, obscure issues with enhanced understandings of exploratory and discovery research in biomedical publications.
- 

Virtual Profiler research assistant to organize publications through visualization, navigation and integration of shared knowledge concepts.
- 

Discover hidden relationships and trends that deliver meaning and insights to relate researcher inquiries and publication knowledge.

2

BioCAID’s IMDI and Profiler technologies integrate Assistive AI knowledge support with Literature Discovery and Hypothesis Generation across a family of Profiler applications and biomedical knowledge services. Our technologies go beyond traditional text and semantic search by building a shared IMDI Associative Relevancy framework from the publications and knowledge resources in the MEDLINE Library, then wrapping that BioCAID IMDI platform around the global MEDLINE ecology as value-added knowledge services. IMDI and Profiler feature intuitive visualization, navigation and integration tools to organize and leverage MEDLINE knowledge as deep learning and decision support services to expand awareness and comprehension of known and hidden relationships for researcher discovery and hypothesis generation across MEDLINE publications. Execution of the BioCAID Mission Statement will facilitate IMDI and Profiler value proposition and technology objectives:

and outcomes for improved research Return on Investment.

WHERE SCIENTIFIC KNOWLEDGE LIVES



The National Institute of Health (NIH) | National Library of Medicine (NLM)

World's largest research library for biomedical, life sciences and healthcare industries and academia today.

The MEDLINE database and MeSH catalog represent the most significant big data text research database for scientific publications and knowledge driving discovery and innovation research.

The MEDLINE database



World's largest biomedical, life science & healthcare research library.



Premier global biomedical library used by an estimated 96% of SME researchers.



Contains references for 28 million peer reviewed publication abstracts in 5,200 journals.



Free to researchers, healthcare providers and the public.



Includes online publication abstracts dating back to 1966.



Indexed with 2.4 million bio-medical terms from the MeSH Catalog.



Mandated by congress to support research awareness and advances.



90 million unique users, conducting 1.2 billion searches annually.



Available to Academic and commercial research professionals, healthcare providers and an estimated 165 million Internet Home Health Search casual users (Pew Research).


The primary user interface to MEDLINE is based on term search referencing the catalog of 2.4 million terms in the MeSH (Medical Subject Heading) thesaurus to catalog and retrieve the scientific publication abstracts in the MEDLINE Library. There is limited insight offered for semantic relationships and other associative knowledge relating terms to each other or to the 28 million MEDLINE publications.

The MEDLINE Library hosted by the NIH National Library of Medicine (NLM) catalogs and stores 28 million scientific publication abstracts supporting 90 million unique users performing over 1 billion searches annually, making MEDLINE the world's largest biomedical research library with free access to researchers and the general public worldwide. MEDLINE and the MeSH meta-thesaurus and related knowledge resources are at the center of a global research ecology based on peer-reviewed scientific publications essential to key stakeholder communities in the biomedical, life science and healthcare industries:

- ✓ Online health-related consumers and patients
- ✓ Universities, faculty and students in the relevant fields
- ✓ Commercial enterprises and researchers in the biotech, drug discovery, healthcare and insurance industries
- ✓ Hospitals, physician groups and healthcare professionals providers and networks
- ✓ Scientific journal publishers.

Although MEDLINE is available to an estimated 165 million Internet Home Health Searchers annually, awareness by the general public of this resource is very low as there is currently no promotional advertising connected with MEDLINE and the unique knowledge resource it represents. Public access and use are further hindered by the complexity and difficulty of the MEDLINE search engine for use by casual Home Health Searchers.


- ✓ MEDLINE user access is based on PubMed Search, essentially a 30-year-old Boolean search engine integrated with a catalog of 2.4 million MeSH terms and publication abstracts.
- ✓ The PubMed Search user experience and features have widely known limitations and frustrations. Crafting advanced PubMed Boolean searches requires several hours and a knowledge skill set possessed by less than 10% of all MEDLINE users.
- ✓ MEDLINE offers no graphic visualization and limited conceptual organization of publication knowledge and term relationships, but does support “find similar documents” and 32 term filters with user search bibliography and citation management.
- ✓ The PubMed Search platform does not offer emerging AI technologies supporting literature discovery for finding hidden relationships, or hypothesis generation suggesting new relationships not currently described in the MEDLINE library.



Scientific Text and Semantic Search technologies provide lists of publications and known relationships in response to queries. The researcher must read these lists of publications and content extracts generated from query terms and analytics to identify, transcribe and classify publications as knowledge that may be related to the researcher's interests. BioCAID takes the user query terms and frames them to visually associate publications and relationships with research interests as intuitive navigable knowledge services for MEDLINE and other biomedical libraries organized by the IMDI platform and Profiler applications. Applications and markets include:


- Supporting University or Teaching Hospital Faculty and Students
- Improving Pharmaceutical and Biotech Drug Discovery efficiency
- Leveraging Research Libraries and Scientific Journal Publishers publication content as knowledge
- Assisting Doctors and Nurses in evidence-based Care Delivery
- Home Health Search Users seeking scientific publications and Doctor-Patient as a Partner relationships
- Pre Research Literature Surveys & Due Diligence, creating a superior baseline knowledge reference for assistive researcher support services and efficiency with increased odds of successful outcome.
- Saving Researcher time, improving effectiveness, reducing failure and raising innovation

ROI



BioCAID has designed the IMDI platform and Profiler applications to go beyond current search and text analytics to deliver a family of Profiler applications featuring assistive relationship cataloging and discovery AI resources as high value knowledge services. This IMDI platform and Profiler application services are wrapped around the global MEDLINE library publication ecology to create IMDI associative frameworks and concepts positioning IMDI platform and Profiler applications as value-added knowledge services leveraging publication research productivity and innovation discovery for stakeholder communities relying on the MEDLINE ecology. BioCAID's strategy is to grow the IMDI platform and monetize it with successive releases of Profiler "Assistive" applications to increasingly sophisticated user communities and markets.

PROFILER FAMILY VISUALIZATION & NAVIGATION



The BioCAID Profiler family of applications integrate proprietary visualization and navigation of 2.4 million MeSH catalog terms from the MEDLINE index integrated with IMDI domain-specific implementations of Associative Relevancy frameworks. Profiler applications support conceptual cataloging of publication and term relationships integrating text analytics, literature discovery of hidden relationships and hypotheses generation of unknown relationships as Profiler knowledge services. Profiler applications support visualization, navigation and integration conceptualization supporting relationship management of terms describing how research interest terms input by the user are related to other library catalog terms with publication terms, including those the user may be unaware of. This is a significant improvement over MEDLINE or Google Search capabilities directly affecting how research is conducted and the effectiveness of innovation discovery and productivity. Profiler visualization and navigation of knowledge relationships is far more informative and intuitive for user comprehension and interaction than a ranked list of term occurrences produced by current search portal platforms of today.

PROFILER P53 BETA RELEASE OBJECTIVES

- 

Illustrates the potential of domain knowledge representation to efficiently and effectively inform users of key relationships not available in ranked search lists
- 

Provides an interactive platform for harnessing the advantages of visual navigation and integration for scientific publications and other published journals
- 

Demonstrates how MEDLINE library resources, such as abstracts and cataloging, can be knowledge-enabled to enhance user awareness, comprehension & innovation ROI from Freemium to Enterprise product markets



7

An early release beta application with limited functionality targeting protein p53 cancer research users across a range of users from general public to professional researchers will demonstrate how the advanced visualization and navigation capabilities of BioCAID literature discovery algorithms work to assist researchers compared with computational literature discovery component of the historic p53 research study conducted by IBM, Baylor University and M. D, Anderson, “*Automated Hypothesis Generation Based on Mining Scientific Literature*”, [KDD '14 Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining Pages 1877-1886](#) in 2014. The BioCAID p53 early release will replicate the literature repository and the search terms used in that study, plus expanded BioCAID IMDI publication abstract references from MEDLINE. The p53 application will also incorporate a beta version of the BioCAID Google Adword campaign to capture user demographics that will be incorporated into the full Basic Freemium Version 1.0 release projected for 6 months after the beta release in month 12 after funding.



BioCAID plans to monetize the IMDI platform through two primary market models, one for Profiler Freemium Adword advertising rollout and one for Profiler Basic Direct Sales rollout. Both models support application upgrade paths. This strategy aligns a 3 year platform development plan with a product marketing strategy targeting successively more sophisticated users and higher value features with correspondingly higher price points, maximizing technology deployment and monetization.

Profiler Freemium is free to all users and derives revenues from an Adword campaign to targeting over 6 million casual Internet Home Health Searchers (HHS) seeking access to the scientific publications in the MEDLINE Library. Freemium goes beyond traditional Search portal competitive technologies, featuring unique semantic concept visualization, navigation and curation applications packaged as an intuitive, easy to understand browser application. The 6 million monthly Internet HHS users seeking access to MEDLINE publications is currently an untapped segment of the online healthcare market that BioCAID intends to pioneer and lead.

BioCAID will add enhanced marketing including targeted email campaigns to offer additional functionality upgrade a predictable percentage of Freemium users to Profiler Basic subscription, adding features for users to save, manage and share their searches and results. Profiler Basic also incorporates features to assist users seeking to locate relevant research by top authors with frequent citations.

Profiler Freemium and Basic users will receive upgrade offers to Profiler Professional supported by development of a BioCAID direct sales strategy. Profiler Professional builds upon search visualization and navigation by adding advanced analytics and discovery algorithms supporting academic and commercial researchers and healthcare professionals and organizations through a monthly subscription plan or license sale. The BioCAID direct sales team will seek to upsell within research centers and universities on our Enterprise release enabling researchers to develop and control their research and public/private communities. Profiler Enterprise adds proprietary publication libraries and knowledge systems and/or services under subscription or licensed pricing and Professional Services.

Searches conducted by Profiler Freemium, Profile Profiler Basic and Profiler Professional will be stored under privacy policies on BioCAID servers to integrate Big Data and analysis of characteristics and outcomes of semantic relationships between terms, publications, users and queries into IMDI learning and reasoning for enhanced knowledge discovery and hypotheses decision support application services.

COMPETITION PROFILER FREEMIUM VERSION

Internet Home Health Search Users					
Key Features	BioCAID Freemium	PubMed MEDLINE	Unbound MEDLINE	Symptom Find.com	Google Scholar
MEDLINE Focused Search	Yes	Yes	Yes	No/Mixed	No/Mixed
Semantic or Boolean Search	Both	Boolean	Boolean	No	No
Similar or Filter Doc Search	Both	Both	Both	No	Both
Term-Term Relevance	Yes	No	No	Partial	Limited
Add Other Peer Collections	Vendor	No	No	No	Vendor
Visual Navigate or HTML List	Visual	HTML	Visual	HTML	HTML
Literature Term Discovery	Yes	No	No	No	No
Big Data Available	Yes	Yes	No	No	No
API Available	No	Yes	Partial	No	Partial
Free or Advertising or SaaS	Advertise	Free	Free	Advertise	Free
Open Source or Patents	Patents	Open	Open	Pending	Open
Curated Search Bibliography	Register	Register	Yes	No	Yes
Author & Citation Support	No	Yes	Yes	No	Limited

Competitive comparisons for Freemium include MEDLINE/PubMed, Unbound Medline and Google Scholar, which are free portals. MEDLINE and Unbound MEDLINE interfaces are based on the PubMed API to access 28 million peer reviewed MEDLINE/PubMed publications. Search technologies are based on Boolean Search, there is no relevance ranking available, only a function for similar documents. Additional retrieval support is available based on up to 32 PubMed filters. Google Scholar includes approximately 200 million various peer docs curated by Google Scholar team with MEDLINE mixed in. Symptomfind is more like a WebMD type portal based on filtered open Internet content term search, and uses an advertising model like Freemium.

COMPETITION PROFILER BASIC SUBSCRIPTION

Key Features	Academic Scholar Search Users				
	BioCAID Profiler Basic	Semantic Scholar	Microsoft Academic	Meaning Cloud	Elsevier Scopus
MEDLINE Focused Search	Yes	No/Mixed	No/Mixed	No/Mixed	No/Mixed
Semantic or Boolean Search	Both	Semantic	Semantic	Semantic	No
Similar or Filter Doc Search	Both	Both	Both	Both	Both
Term-Term Relevance	Yes	Limited	Yes	Yes	Limited
Add Other Peer Collections	Vendor	Vendor	Vendor	Vendor	Vendor
Visual Navigate or HTML List	Both	HTML	HTML	HTML	HTML
Literature Term Discovery	Yes	Yes	Yes	Yes	Partial
Big Data Available	Yes	No	Yes	Yes	No
API Available	Yes	Yes	Yes	Partial	Partial
Free or Advertising or SaaS	SaaS	Free	SaaS	SaaS	SaaS
Open Source or Patents	Patents	Open	Mixed	Patents	Mixed
Curated Search Bibliography	Yes	Yes	Yes	Yes	Yes
Author & Citation Support	Yes	Yes	Yes	Limited	Yes

10

Profiler Basic is a subscription based upgrade to the Freemium offering that removes the advertising component and adds additional features for academic researchers and more sophisticated Home Health Searchers seeking regular access to MEDLINE and author publication citations to support and organize scientific research for literature surveys and related activities. These applications support controlled libraries of publication records and do not include open Internet results. Competitors Google Scholar and AI2 Semantic Scholar are free. Google Scholar is 10 years old Google Search covers a curated repository of about 200 million peer and non-peer scientific papers and articles. Semantic Scholar offers a more sophisticated and capable semantic search with a curated repository of about 80 million peer and non-peer scientific papers. Microsoft Academic is subscription pricing, and includes semantic search with a vendor curated repository of about 70 million peer and non-peer scientific papers. Elsevier is subscription pricing, has no semantic search but includes a vendor curated repository of about 60 million peer scientific papers.

COMPETITION PROFESSIONAL VERSION

Professional Research Users & Enterprise Platforms						
Key Features	BioCAID Professional	BioCAID Enterprise	Microsoft Sharepoint	BIOVIA Linguamatic	Accenture Searchlight	IBM-Baylor P53 Study
Semantic or Boolean Search	Both	Both	Both	Both Limited	Both Limited	Limited to p53
Similar or Filter Doc Search	Both	Both	Both	No	Both	Both
Term-Term Relevance	Yes	Yes	Yes	Partial	Yes	Yes
Visual Navigate or HTML List	Both	Both	Both	Limited	Limited	Limited
Literature Term Discovery	Yes	Yes	Yes	Yes	Yes	Limited to p53
Hypotheses Decision Support	Yes	Yes	Limited	Limited	Limited	Limited to p53
Big Data Platforms & Analytics	Yes	Yes	Yes	Yes	Yes	Limited to p53
Application Programming Interface	Yes	Yes	Yes	Yes	Yes	Yes
Natural Language Processor	Yes	Yes	Yes	Yes	Yes	Yes
Add Other Peer Collections	Yes	Yes	Yes	No	Vendor	Vendor
Third Party Knowledge Integration	Patents	Patents	Patents	Patents	Patents	Unknown
Automated Literature Annotation	Partial	Yes	Yes	Partial	Partial	No
Search & Citation Tools & Curation	Yes	Yes	Yes	Yes	Yes	Partial

11

BioCAID Professional and Enterprise applications incorporate all features in Profiler Basic with expanded resources for user-configurable visualization, navigation, integration and curation that can be tailored to each Profile created by the user. Literature Discovery of hidden relationships and Hypotheses Decision Support algorithm toolsets like Pairwise, Substitution, Text/Data Mining, Natural Language Processing and trending can be accessed and configured by the user and/or group in a shared research project community. Third party knowledge system frameworks can be integrated with the IMDI platform as well as other text/data repositories based on proprietary customer knowledge and information. The Enterprise version adds controlled semi-automated and automated literature cataloging, annotation and integration for multiple repository configurations such as drug discovery, clinical trials, proprietary libraries, etc.

Microsoft SharePoint, BIOVIA Linguamatic and Accenture Searchlight represent the document/text component of end to end Enterprise research project management, users, analytics and curation. Professional services are required for installation of these products and services. The end result is a multi-repository discovery platform tuned to a specific research project such as the IBM-Baylor p53 Study, which is limited to 70,000 publications out of the 28 million publications available in MEDLINE. This is the industry standard, and requires Subject Matter Experts identify, read and annotate each publication into the discovery repository. This is a very costly but highly valuable resource that BioCAID estimates the Enterprise platform applications will reduce by a factor of 10.



BioCAID's Roll Out Plan builds on prior research to leverage phased technology development releases of successive application features and market sophistication .

Current. Prototype applications have been built, tested and validated in peer reviewed publications. An IP portfolio supporting a value chaining strategy leveraging semantic search and literature discovery has been developed. Formation of BioCAID, Inc. as Go To Market company for IP and technology assets developed by Araicom Research, LLC.

Month 1. Execute and fund Series A PPM.

Month 6. Beta release Profiler p53 literature discovery application demonstrating visual navigation of domain knowledge for cancer research associated with protein p53 knowledge extracted from related MEDLINE publications, terms and cataloging. The p53 Beta application will be tested across a range of users from general public to professional researchers to demonstrate and assess how the advanced visualization and navigation capabilities of BioCAID work to assist users.

Month 12. Launch 'Freemium' application to primary target market 6 to 8 million unique monthly HHS users seeking biomedical publications. Secondary market is 6.4 million US graduate and undergrad students in biomedical, life sciences and healthcare fields.

The Profiler Freemium Adword Ecommerce Model targets the 6.8 million monthly Internet Home Health Search (HHS) users identified by Google, Bing and other sources as seeking access to

scientific publications and libraries. Our revenue basis for the Freemium 1.0 release is very predictable with validation based directly on Google projections, and includes a 3 month lag for “invoice to cash in bank”. During this period we will complete the development of the Profiler Basic application that allows academic scholars and commercial researchers as well as sophisticated Freemium users to upgrade to a subscription based account to save and share their searches, results and findings. Site licenses for organizations and for co-branded partner agreements are also supported.

Month 16. Begin Freemium revenues booked to bank. Launch Profiler Basic application and email campaign rollout of BioCAID’s direct sales market and channel distribution strategy targeting professional researcher markets.


Month 25. Launch Profiler Professional direct sales campaigns; ramp-up direct sales team; include upgrade offers in on-going direct email campaigns. Begin print media ads and conference exhibits.

Profiler Professional application release is planned for 24 months after funding with an advanced feature set that is attractive to academic and commercial professional researchers, doctors, nurses and similar users at organizations including Universities, independent labs and biotech and drug discovery enterprises. Profiler Professional supports data structures for users, terms, queries, results and other demographics in public/private repository infrastructures supporting sharable IMDI data services and repositories. In addition to multiple monetization opportunities BioCAID plans to develop, the IMDI AI system uses these data repositories to enhance learning and reasoning characteristics of the IMDI platform and Profiler Professional cataloged discovery of hidden relationships. These features are further expanded in Profiler Enterprise to support previously unknown relationship hypotheses decision support algorithms and cataloging.

Month 22. Profitable operations reached.

Month 36. Launch IMDI, ARRE, and Precompute Enterprise platform and Profiler Enterprise users targeting the STM-MEDLINE ecology with sophisticated literature discovery and hypothesis features leveraging proprietary discovery research platforms.

Profiler Enterprise application is projected for release 36 months after development funding to support Enterprise users and platform services for public/private configurations supporting universities, scientific publishers and libraries, biotech and pharmaceutical research platforms with internal enterprise licenses for customer controlled research access. The Enterprise platform will offer advanced professional researcher and group domain services with analytic and algorithmic literature discovery and hypotheses decision support toolbox and automated document/term annotation services for custom research repository platform applications.



The 4 versions of applications offered on the IMDI platform are shown as revenue begins at the end of year one, following the success of the beta release in year one. Revenue from Freemium lags the ad delivery by 3 months after the first ad activity, and coincides with the estimated delivery and first upgrade activity to Profiler Basic. As the professional is introduced in year 2 followed by the enterprise versions released in year 3, all versions available for direct sales and digital marketing upsell by year 3. Year 4 shown here reflects only the first 6 months of the year. We expect the Profiler Freemium to maintain at about that level because of the churn of limited search users, and the limited time use of those professionals seeking the greater function of Profiler Basic and Professional. You see here the compounding effect of a growing ad revenue model that has a perpetual new potential user base from the new Home Health Searchers entering the market every month. Within our assumptions on customer behavior to derive our revenue forecast, we assume Profiler Professional users will quickly upgrade after a short trial period in the Freemium version, if they are not already using Profiler Basic when the Professional version is offered. Therefore, we assume that there will be attrition of users from Basic to Professional, and some users will skip the Basic version all together once the Professional version is available as an upgrade path from Freemium. Most Enterprise users will likely follow an upgrade path from Freemium, to limited Professional subscriptions within the team, to full Enterprise license and even private label version for internal Enterprise secure platform.

Our assumption include the expectation there both the Profiler Freemium and Basic will settle in at about the \$100M mark for a full year of sales, and the Professional will be the most desired version and easiest to upsell, going from \$231 M in the year it is introduced, continuing to grow over

\$600M in a full sales year. Enterprise has a different use case and ROI to the institution implementing it, this figure for the first 6 months of its availability at nearly \$25M includes the license fees plus professional service fees for implementation. Our total estimated cumulative revenue at the end month 42 is over \$900 Million.

Financial Projections	Year 1	Year 2	Year 3	Year 3 (6 Months)
Gross Sales Revenue	0	32,165,000	404,742,000	465,440,000
EBITDA	No Debt	No Debt	No Debt	No Debt
Pre-Tax Income (1,603,000)	24,296,000	387,723,000	451,456,000	
Net Income After 21% Tax	(1,603,000)	19,193,840	306,301,170	356,650,240

Use of Funds

- * Commercialization of BioCAID IMDI platform technology & user applications
- * Testing of the SaaS platform services & user application interface
- * Patent filings with innovation disclosures for strategic research
- * Go to market sales strategy refinement & implementation
- * Partner negotiations & agreements
- * Market entry and product launch into profitable operations
- * Research grant RFP opportunities

BIOCAID TEAM

Anthony Prestigiacomio
Chief Executive Officer, Board Chairman

Rajnish Gupta
Chief Technology Officer, Board Member

Dr. John F. Prestigiacomio
Chief Science Officer, Board Member

Karen Rands
Financial Advisor, Director of Business Development, Board Member

Active Advisor/Team Recruitment
Digital Marketing Expertise, Digital Advertising, Enterprise Sales Expertise
Software Operations Expertise, IT Architecture, Interim CFO & CMO
Future: Customer Service, User Experience, Tech Support, Data Management, Marketing & Sales

14

Anthony Prestigiacomio and Rajnish Gupta are familiar with the needs of researchers and enterprises, with deep knowledge of the NIH National Library of Medicine and advanced resources such as MeSH (Medical Subject Headings) and UMLS (Unified Medical Language System) meta-thesauri and related professional vocabularies as well as participation with NIH initiatives such as the National Cancer Institute’s caBIG global cancer research computational data grid and related data services platforms; computational methodologies for text/data platforms including Natural Language Processing and research and development of biotech and drug discovery platforms as well as broad knowledge of text/data dbms platforms and development languages. Both men have peer reviewed publications, and are co-inventors of the IMDI platform patent and technologies currently under development.


Dr. John F. Prestigiacomio has 30 years experience with the healthcare industry and coded terminology vocabularies and active MEDLINE usage. He has acted as a Subject Matter Expert over the past 12 years working with Anthony Prestigiacomio and Araicom Research. Dr. Prestigiacomio has an active practice and is a Certified member of the American Academy of Family Physicians (AAFP). Dr. Prestigiacomio has an MBA with healthcare industry concentration.

Karen Rands has deep experience with translating technology innovation and

entrepreneurship opportunities into business opportunities for private placement and institutional funding. Karen currently has a best selling book, "Inside Secrets to Angel Investing" and has developed methodologies for Angel assessment and funding of entrepreneurial private placement opportunities.



BioCAID, Inc. has authorized a Series A PPM and convertible notes with capitalization valuation prepared and managed by BioCAID’s Corporate Attorney and Karen Rands. Investor documents and business plan with references and investor due diligence documents are available on request through the Investor portal on the www.biocaid.com website or contact Karen Rands or Anthony Prestigiacomo.


A presentation slide for BioCAID Inc. with a blue and grey geometric design on the left and a blurred photo of people at the bottom. The slide contains contact information for the CEO and Investor Relations, the company's address, website, and a request to email for direct contact numbers.


QUESTIONS AND FOLLOW UP

Anthony Prestigiacomo, CEO **Karen Rands, Investor Relations**
tpresti@biocaid.com krands@biocaid.com

BioCAID Inc.

 BioCAID, Inc
108 Brookwood Path, Suite 200
Atlanta, GA 30269

 www.biocaid.com

 Please email us for
direct contact phone
numbers

Additional information is available at www.biocaid.com website including a portal for investor inquiries and access to BioCAID investor documents and due diligence references. Please email Anthony or Karen for our direct contact phone numbers or for any questions you may have.